239 related articles for article (PubMed ID: 10604724)
1. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines.
te Poele RH; Joel SP
Br J Cancer; 1999 Dec; 81(8):1285-93. PubMed ID: 10604724
[TBL] [Abstract][Full Text] [Related]
2. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
McDonald AC; Brown R
Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293
[TBL] [Abstract][Full Text] [Related]
3. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential.
Wallin A; Svanvik J; Holmlund B; Ferreud L; Sun XF
Oncol Rep; 2008 Jun; 19(6):1493-8. PubMed ID: 18497955
[TBL] [Abstract][Full Text] [Related]
4. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth.
Bhonde MR; Hanski ML; Notter M; Gillissen BF; Daniel PT; Zeitz M; Hanski C
Oncogene; 2006 Jan; 25(2):165-75. PubMed ID: 16170360
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Tse AN; Schwartz GK
Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
[TBL] [Abstract][Full Text] [Related]
6. Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.
Bozko P; Larsen AK; Raymond E; Skladanowski A
Acta Biochim Pol; 2002; 49(1):109-19. PubMed ID: 12136930
[TBL] [Abstract][Full Text] [Related]
7. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status.
Magrini R; Bhonde MR; Hanski ML; Notter M; Scherübl H; Boland CR; Zeitz M; Hanski C
Int J Cancer; 2002 Sep; 101(1):23-31. PubMed ID: 12209584
[TBL] [Abstract][Full Text] [Related]
8. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
9. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Azzariti A; Xu JM; Porcelli L; Paradiso A
Biochem Pharmacol; 2004 Jul; 68(1):135-44. PubMed ID: 15183125
[TBL] [Abstract][Full Text] [Related]
10. Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy.
Miettinen S; Ylikomi T
Anticancer Drugs; 2009 Aug; 20(7):589-600. PubMed ID: 19491654
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y
Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856
[TBL] [Abstract][Full Text] [Related]
12. P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative.
Xie X; Sasai K; Shibuya K; Tachiiri S; Nihei K; Ohnishi T; Hiraoka M
Cancer Chemother Pharmacol; 2000; 45(5):362-8. PubMed ID: 10803918
[TBL] [Abstract][Full Text] [Related]
13. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis and cell cycle-specific change in expression of p53 in normal lymphocytes and MOLT-4 leukemic cells by nitrogen mustard.
Bhatia U; Danishefsky K; Traganos F; Darzynkiewicz Z
Clin Cancer Res; 1995 Aug; 1(8):873-80. PubMed ID: 9816057
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
Crea F; Giovannetti E; Cortesi F; Mey V; Nannizzi S; Gallegos Ruiz MI; Ricciardi S; Del Tacca M; Peters GJ; Danesi R
Mol Cancer Ther; 2009 Jul; 8(7):1964-73. PubMed ID: 19531575
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and radiotherapy: sequence-dependent efficacy--a preclinical model.
Niero A; Emiliani E; Monti G; Pironi F; Turci L; Valenti AM; Marangolo M
Clin Cancer Res; 1999 Aug; 5(8):2213-22. PubMed ID: 10473108
[TBL] [Abstract][Full Text] [Related]
17. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
Xu JM; Azzariti A; Tommasi S; Lacalamita R; Colucci G; Johnston PG; Church SW; Paradiso A
Clin Colorectal Cancer; 2002 Nov; 2(3):182-8. PubMed ID: 12482336
[TBL] [Abstract][Full Text] [Related]
18. DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis.
Bhonde MR; Hanski ML; Budczies J; Cao M; Gillissen B; Moorthy D; Simonetta F; Scherübl H; Truss M; Hagemeier C; Mewes HW; Daniel PT; Zeitz M; Hanski C
J Biol Chem; 2006 Mar; 281(13):8675-85. PubMed ID: 16446370
[TBL] [Abstract][Full Text] [Related]
19. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
20. p53 status, cellular recovery and cell cycle arrest as prognosticators of in vitro radiosensitivity in human pancreatic adenocarcinoma cell lines.
Ng CE; Banerjee SK; Pavliv M; Wang G; Raaphorst GP; Aubin RA
Int J Radiat Biol; 1999 Nov; 75(11):1365-76. PubMed ID: 10597911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
